ADVM vs RARE vs BMRN vs SRPT vs EDIT

For growth investors, Ultragenyx Pharmaceutical Inc.

(RARE) is the stronger pick with 20. 1% revenue growth year-over-year, versus -100. 0% for Editas Medicine, Inc. (EDIT). BioMarin Pharmaceutical Inc. (BMRN) offers the better valuation at 30. 0x trailing P/E (13. 6x forward), making it the more compelling value choice. Analysts rate Ultragenyx Pharmaceutical Inc. (RARE) a "Buy" — based on 33 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Sarepta Therapeutics, Inc.

is actually cheaper at 5. 9x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, BioMarin Pharmaceutical Inc.

(BMRN) delivered a total return of -29. 2%, compared to -90. 1% for Editas Medicine, Inc. (EDIT). Over 10 years, the gap is even starker: SRPT returned +13. 2% versus EDIT's -89. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), BioMarin Pharmaceutical Inc.

(BMRN) is the lower-risk stock at 0. 64β versus Editas Medicine, Inc. 's 2. 45β — meaning EDIT is approximately 285% more volatile than BMRN relative to the S&P 500. On balance sheet safety, BioMarin Pharmaceutical Inc. (BMRN) carries a lower debt/equity ratio of 11% versus 130% for Adverum Biotechnologies, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Ultragenyx Pharmaceutical Inc.

(RARE) is pulling ahead at 20. 1% versus -100. 0% for Editas Medicine, Inc. (EDIT). On earnings-per-share growth, the picture is similar: Editas Medicine, Inc. grew EPS 37. 5% year-over-year, compared to -404. 7% for Sarepta Therapeutics, Inc.. Over a 3-year CAGR, SRPT leads at 33. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

BioMarin Pharmaceutical Inc.

(BMRN) is the more profitable company, earning 10. 8% net margin versus -130. 9% for Adverum Biotechnologies, Inc. — meaning it keeps 10. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BMRN leads at 16. 6% versus -139. 2% for ADVM. At the gross margin level — before operating expenses — ADVM leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Sarepta Therapeutics, Inc.

(SRPT) trades at 5. 9x forward P/E versus 13. 6x for BioMarin Pharmaceutical Inc. — 7. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for RARE: 85. 1% to $48. 36.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, BioMarin Pharmaceutical Inc.

(BMRN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 64)). Editas Medicine, Inc. (EDIT) carries a higher beta of 2. 45 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BMRN: -35. 6%, EDIT: -89. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ADVM is a small-cap quality compounder stock; RARE is a small-cap high-growth stock; BMRN is a mid-cap quality compounder stock; SRPT is a small-cap high-growth stock; EDIT is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.